复星医药的创新叙事,留下了新的注脚。近期,在中国医药新闻信息协会主办的“2025新时代讲好医药故事”活动中,复星医药凭借其自主研发的高选择性MEK1/2抑制剂芦沃美替尼(商品名:复迈宁®)入选“最佳案例”。复星医药传递的故事内核简单而有力——芦沃美替尼以双适应症上市,填补罕见肿瘤疾病治疗空白。或许在不少人眼中,芦沃美替尼治疗罕见肿瘤这个故事看起来不够性感,但它蕴藏的社会价值却是很多药物无法比拟的—...
Source Link复星医药的创新叙事,留下了新的注脚。近期,在中国医药新闻信息协会主办的“2025新时代讲好医药故事”活动中,复星医药凭借其自主研发的高选择性MEK1/2抑制剂芦沃美替尼(商品名:复迈宁®)入选“最佳案例”。复星医药传递的故事内核简单而有力——芦沃美替尼以双适应症上市,填补罕见肿瘤疾病治疗空白。或许在不少人眼中,芦沃美替尼治疗罕见肿瘤这个故事看起来不够性感,但它蕴藏的社会价值却是很多药物无法比拟的—...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.